TNFRSF17 and plasma cell myeloma: BCMA is already an established target in the treatment of multiple myeloma, using either bispecific antibody constructs, antibody–drug conjugates or chimeric antigen receptor (CAR)-modified T cell therapies [43], and could represent an attractive novel therapeutic target in SLE for depleting plasma cells together with memory B cells.